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Natural herbal medicine (NHM) has been used to control infectious diseases for thousands of
years. In view of the possible beneficial effect of NHM on SARS, we conducted this study to
examine whether NHM is of any benefit as a supplementary treatment of SARS or SARS-like
infectious disease. This was a randomized, double-blind, placebo-controlled trial. Twenty-eight
patients fulfilled the WHO inclusion criteria and our exclusion criteria. All enrolled patients
received routine western-medicine treatment. Patients were randomly allocated to one of
the three supplementary treatment groups: NHM A (Group A, n¼9) NHM B (Group B, n¼9)
or placebo (Group C, n¼10). Chest X-ray was done every 1 or 2 days for every patient.
Reading radiologists use a standard 0–3 scoring system (0: no infiltration; 1: focal haziness or
even small patchy lesion; 2: ground glass picture; 3: lobar consolidation) according to the
severity of infiltration in each lung field (three lung fields in both right and left lungs).
The main outcome measurements were the improving chest radiographic scores (IRS) and the
duration (days) till improvement (DI). One patient from the placebo group passed away.
Patients from NHM A took less days before showing improvement (6.7 1.8) compared with
placebo group (11.2 4.9), which showed statistical significance (P¼0.04). The cases were
too few to be conclusive, the initial observations seem to indicate NHM appears to be safe in
non-criticallly ill patients and clinical trials are feasible in the setting of pandemic outbreaks.
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Introduction
As of August 15, 2003, the cumulative SARS cases
reported to the WHO from 29 countries were 8098, with
774 deaths (1,2). A novel coronavirus is the cause of this
disease (3–5). Because the pathogenesis is still under
study, there is no effective treatment as yet (6). Although
many guidelines or protocols have been proposed (7,8),
there are few well-designed studies. Natural herbal
medicine (NHM) has been used to control infectious
diseases for thousands of years. In view of the possible
beneficial effect of NHM on SARS or SARS-like
infectious diseases, we conducted this randomized,
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ine its effectiveness.
Method
Setting and Patients
Our hospital (Taipei Hospital, Taiwan) was committed to
take care of local SARS patients in the middle of March,
2003. A 52-bed ward was rebuilt as negative pressure
seclusion rooms to admit SARS patients.
The subjects were recruited from April 25, 2003 to
June 30, 2003. They were admitted via the out-patient
department and emergency service of our hospital, or
transferred from other hospitals. All the patients met the
WHO inclusion criteria (9). We excluded aged patients
over 55 years, patients younger than 18 years old, and
those with severe clinical conditions such as endotracheal
intubation or unstable vital signs from the beginning
(Table 1, Fig. 1). The protocol was approved by the
Human Ethics Committee of our hospital.
A clinical herb trial notification and a letter in which
we explained how to take the NHM were given soon
after the patient was admitted. Chinese herbal doctor
would explain the details of the study and maintained
close communication with the patient during the course
of study. Informed consent was obtained from all the
enrolled patients. The patients were free to withdraw
from the study at any time.
Randomization and Blindness
Every subject was randomly assigned to one of the
groups by computer. The SARS patients were isolated in
the negative pressure seclusion wards having no contact
with other patients. Thus, the patients were fully blind to
the herb trial.
We provided two teams to care for the SARS patients,
the western medical team and the Chinese medical team.
The latter was responsible for Chinese-herb preparation
and consultation. These two teams worked cooperatively
but independently. The western medical doctors remained
unaware of the herbal regimens and their effect.
To avoid bias from the radiologists who read the chest
X-ray films, we substituted the chart number labeled on
the X-ray films with a different number before submitting
them for reading. Thus, our reading radiologists also
remained unaware of the study procedures.
Herb Preparation and Treatment
NHM A was designed by our Chinese-herb consulting
physician team according to the theory of Chinese
medicine and our clinical experience. A total of 13
different kinds of herbs with 6–16mg of each ingredient
made up the formula (Table 2), which were popular be
used in Taiwan and buy from the same Chinese medicine
shop with certificate of standardized given. A sachet of
NHM A weighed 120gm, to which we added 600ml
water and simmered for 30min until only 250ml of
decoction remained. NHM B was a health-care product
popularly used in Taiwan, which was made from the
elixir of Agaricus brazei Murill, Panax ginseng and
Cordyceps sinensis (10–12). Every day, 250ml of this
elixir, diluted 1:200 with water, were taken by the subject.
Placebo-control was 250ml of 1:200 diluted brown sugar
water.
To maintain the quality of the NHM, the Chinese-
medicine doctors who participated in the project had to
undergo a training on NHM preparation. The first CHM
or placebo was administered within 12h after the patient
was admitted. The treatment lasted throughout
hospitalization.
Table 1. Inclusion (WHO criteria
9) and exclusion criteria
Inclusion criteria
Suspect case
A person presenting with history of high fever (438 C) AND cough or breathing difficulty
And one or more of the following exposures during the 10 days prior to onset of symptoms:
- close contact with a person who is a suspect or probable case of SARS;
- history of travel to an area with recent local transmission of SARS
- residing in an area with recent local transmission of SARS
Probable case
(i) A suspect case with radiographic evidence of infiltrates consistent with pneumonia or respiratory distress syndrome (RDS) on chest
X-ray (CXR).
(ii) A suspect case of SARS that is positive for SARS coronavirus by one or more assays.
Exclusion criteria
At the time of entry into the study, a case should be excluded:
(I) If an alternative diagnosis can fully explain the illness.
(II) Age 518 and 455 years
(III) More than 10 days from the date of onset of fever, on endotrachea tube, or in severe conditions with other multiple medical problems.
(IV) GOT, GPT4100 U/l, serum creatinine 42.5mg/dl
(V) Breastfeeding or pregnant women.
(VI) Taken any Chinese herbs in the last 3 months
(VII) Any other conditions not suitable for trial as evaluated by the physician on duty.
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The western medical doctors in charge of the SARS
patients prescribed routinely the following.
(i) Robatrol (Ribavirin, 200mg) 10 tablets loading,
then 2 tablets am and three tablets pm for 10–14
days.
(ii) Klaricid (Clarithromycin, 250mg) two tablets, bid,
for 10–14 days.
In case the respiratory symptoms aggravated, the patients
were usually given extra steroid, such as methylpredni-
solone (Solu-Medrol, 40mg) 1 vial intravenous injection
every 8 hours for a 2–3day course, and the dose then
tapered. If acute respiratory distress syndrome developed,
they administered intravenous immunoglobulin (IVIG in
short, Octagam, Gamimune, 2.5g in 50ml) 20–30 vials
intravenous drip for 6–8 hours per day for two
consecutive days.
Figure 1. Trial profile.
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The chest X-ray film was reported to be the standard
assessment and compatible with the progression of SARS
(7,10,11). Chest X-ray was done 1 or 2 days for every
SARS patient. Our reading radiologists use a standard
0 to 3 scoring system (0: no infiltration; 1: focal haziness
or even small patchy lesion; 2: ground glass picture;
3: lobar consolidation) according to the severity of
infiltration in each lung field (three lung fields in both
right and left lungs). The scores were then added up to a
total of 0–18 scores for each film (7). Three radiologists
gave the scores of the serial films independently. If the
scores reached 12, denoting a poor condition, the patient
would be transferred to the intensive care unit (ICU) and
intubation was considered. The main outcome measure-
ments were the IRS and the DI, which were defined
as follows.
IRS¼Maximal Score (MS) Final Score (FS).
DI¼Duration (days) between the MS day and FS
day,where MS day is the day on which the most severe
condition was read during hospitalization; and FS day is
the day on which the patient’s condition is improved
or become stabilized.
Laboratory and Clinical Presentations
All nasopharyngeal washing specimens, deep throat
gargles and blood of the patients were submitted to our
Disease Control Bureau for SARS-CoV polymerase chain
reaction (PCR) examination (13–17). We also sampled
the patients’ serum during hospitalization and after
discharge for SARS-CoV antibody (16–19). The antibody
and conditions used in indirect immunofluorescence test
(IIFT). The method employed for antibody test was
IIFT. Antibody titers were reported according to the
intensity of fluorescence obtained at different sample
dilutions. A serum dilution of 1:10 or higher with weaker
or stronger fluorescence in SARS-CoV-infected cell
cytoplasm was evaluated as positive. Two sets of
sample were sent to our Disease Control Bureau and
our laboratory for double testing. We collected simulta-
neously the demographic data, initial symptoms, vital
signs of the subjects during the in-patient period.
The serial laboratory data taken every 1–3 days included
white blood cell count, platelet count, lymphocyte count,
alanine aminotransferase, creatine kinase, lactate dehy-
drogenase and creatinine.
Statistical Analysis
Outcome was measured with student t-test to evaluate the
difference between the groups. The other data were
evaluated with ANOVA or chi-square test according to
the data characteristics. All P-values were two-tailed and
the a-level of significance was set at 0.05.
Results
Demographic
Among the 56 patients admitted to the negative pressure
seclusion wards of Taipei Hospital in Taiwan, 36 patients
fulfilled the diagnostic criteria of either suspected or
probable SARS (Fig. 1). Of the 36 subjects, 8 were
excluded. We randomly assigned the patients into three
groups. Three patients were transferred to other hospitals
due to personal reason (transferred to the same hospital
with their family). One patient of Group C died on the
ninth day. In the end, 24 patients completed the study
(Fig. 1). The demographic and clinical profiles of each
group at the time of admission were indistinguishable
from one another (Table 3).
Outcomes
The chest X-ray scores at initial (IS), maximal (MS), and
final (FS) stages were compared (Table 4). No significant
statistical difference in chest radiographic scores was
found among the groups. Patients from group A took
less days before showing improvement (6.7 1.8)
compared with Group C (11.2 4.9), which showed
statistical significance (P¼0.04).
Expired Case
A 36-year-old female patient in Group C passed away,
her severe radiographic scores were 16 on the ninth day
after onset of disease. Her condition deteriorated fast.
After endotracheal intubation and being transferred to
the ICU, she died the next day.
Table 2. Natural herbal medicine A composition
Chinese name Pharmaceutical name Dose
(gm)
Weight
(%)
Shi Gao Gypsum fibrosum 16 13.3
Chai Hu Bupleurum chinenese 12 10
Zhi Zi Gardeniae jasminoides 12 10
Fang Fong Siler divaricatum 10 8.3
Huang Gin Scutellaria baicalensis 10 8.3
Qiang Huo Notopterygium incisium 8 6.7
Jing Jie Schizonepeta tenuifolia 8 6.7
Fu Ling Poria cocos 8 6.7
Shao Yao Paeoniae lactiflorae 8 6.7
Ban Xia Pinellia ternata 8 6.7
Hua Xiang Agastache rugosa 8 6.7
Jie Geng Platycodon grandiflorum 65
Mai Men Dong Ophiopogon japonicus 65
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Group A
Mean (SD) (n¼8)
Group B
Mean (SD) (n¼8)
Group C
Mean (SD) (n¼8)
P
Variables
Age, years old 34.8 (9.4) 39.9 (13.2) 39.5 (8.8) 0.46
Sex ratio, 8: 9 3:5 5:3 4:4 0.61
Positive of PCR or antibody rate 0.5 0.6 0.6 0.84
Days after disease onset before enrolled in the trial 3.3 (1.0) 3.3 (2.0) 3.5 (1.6) 0.94
Initial vital signs
Body temperature,  C 38.5 (0.8) 38.1 (0.7) 38.4 (0.8) 0.56
Systolic blood pressure; mmHg 121.0 (16.1) 121.1 (16.8) 118.8 (16.1) 0.65
Diastolic blood pressure, mmHg 77.6 (13.6) 77.4 (15.0) 69.8 (13.3) 0.45
Respiratory rate, times/min 21.8 (1.2) 21.1 (1.7) 22.6 (4.4) 0.57
Heart rate, beats/min 95.3 (13.6) 99.8 (17.2) 95.5 (19.3) 0.84
O2 saturation
z (%) on room air 97.5 (1.4) 95.4 (4.0) 97.6 (1.0) 0.16
Initial symptoms rate
Fever (438 C) 1.0 1.0 1.0 1.0
Cough 0.6 0.9 0.9 0.36
Diarrhea 0.8 0.3 0.4 0.11
Received drug rate
Robatrol 1.0 1.0 0.9 0.35
Intravenous immunoglobulin 0.1 0.0 0.1 0.58
Steroid 0.4 0.5 0.6 0.61
Antibiotics 1.0 1.0 1.0 1.00
Initial data
Radiographic scores 2.1 (1.2) 2.5 (1.6) 3.0 (2.7) 0.67
Lymphocytes, 10
 9/l 1.4 (0.7) 1.0 (0.7) 1.3 (0.6) 0.71
Platelets, 10
 9/l 235.1 (150.1) 186.8 (56.9) 182.5 (74.6) 0.66
Creatine Kinase, U/l 281.5 (360.1) 188.3 (130.9) 156.3 (92.6) 0.53
Lactate dehydrogenase, U/l 268.8 (132.9) 287.0 (120.8) 194.5 (46.3) 0.21
Creatinine, mg/dl 1.0 (0.4) 1.0 (0.2) 0.9 (0.3) 0.93
Table 4. Analysis of outcomes
Group A
(n¼8)
Group B
(n¼8)
Group C
(n¼8)
P–value Comparison between group
Outcomes Mean (SD) Mean (SD) Mean (SD) A, B B, C A, C
Chest radiographic scores
Initial (IS) 2.1 (1.2) 2.5 (1.6) 3.0 (2.7) 0.57 0.69 0.43
Maximal (MS) 5.9 (3.5) 5.6 (3.4) 7.9 (4.0) 0.85 0.23 0.31
Final (FS) 0.7 (0.9) 0.5 (0.6) 2.7 (3.4) 0.75 0.12 0.15
IRS
a 5.3 (3.7) 5.0 (3.5) 5.6 (4.7) 0.91 0.91 0.99
Duration (days) till improvement
Worsening (DW)
b 5.5 (4.2) 3.8 (2.8) 7.8 (5.7) 0.36 0.10 0.37
Improvement (DI)
c 6.7 (1.8) 9.2 (5.9) 11.2 (4.9) 0.28 0.47 0.04
Course (DC)
d 12.2 (5.0) 13.0 (7.8) 19.0 (10.0) 0.81 0.20 0.11
aIRS (Improving Radiographic Scores), MS – FS;
bDW, Duration (days) between IS to MS;
cDI, Duration (days) between MS to FS;
dDC, DWþDI
[Duration (days)].
eCAM 2008;5(3) 359Adverse Effects
No patients withdrew from the study because of
discomfort or adverse effects associated with the treat-
ment. Three patients developed mild diarrhea and one
patient had upper abdominal discomfort after taking
NHM A. No major adverse effects were noticed.
Discussion
Large outbreaks of SARS occurred in China (5327 cases
with 349 deaths) Hong Kong (1755 cases with 299
deaths) and Taiwan (346 cases with 37 deaths); account-
ing for 91.7% of cumulative cases and 88.5% of total
death globally (2). According to Treatise on Febrile
Disease (Shang Han Lun), a variety of herbal formulas
have been employed to treat patients with infectious
diseases for over 1800 years. When the outbreak began in
Guandong, NHM had already been anecdotally used as a
supplementary regimen. Therefore, we had conceived the
trial strategy before the SARS outbreak that occurred at
the end of April in several hospitals in Taiwan. NHM is
generally well accepted among the Chinese population;
95% of our patients agreed to participate in our study.
In fact, many anecdotal reports have been proposed on
the use of NHM for SARS patients, unfortunately none
was a controlled trial (20).
To our knowledge, this is the first double-blind and
placebo-controlled clinical pilot study on supplementary
treatment of SARS or SAR-like diseases. SARS patients
were in strict seclusion and were cared for independently
by the SARS care team. The NHM preparation was
provided by another Chinese medical team. Therefore,
neither patients nor doctors-in-charge knew to which
herbal trial group each patient was assigned. The SARS
care team held daily meeting at 5:00pm to discuss the
patients’ conditions, treatment strategy and SARS con-
trol measures in the hospital. The Chinese medical team
did not interfere with the management decision on each
patient.
Related papers showed that younger children seem to
have a less aggressive clinical course (21). Our young
case, a 5-year-old child with positive SARS-CoV PCR,
also had mild symptoms (only cough, fever, diarrhea,
chest X-ray score of 1, chest radiographs showing
complete resolution within 5 days). Advanced age and
the presence of underlying medical illness have been
reported to be risky factors for severe course (6,22–26).
All probable SARS patients in Canada who required
intubation or died had either underlying medical illnesses
or were older than 55 years of age (6,14,24). So we
excluded patients of old (455years) and young age
(518 years), those with complicated underlying medical
illness, and those already intubated from the beginning of
our study.
All probable SARS patients showed infiltration on
chest radiography (7,13,14). The radiographic feature of
pneumonia is also one of the SARS diagnostic criteria
(9). Chest radiographic finding is compatible with the
condition of disease (6,7,25,26). The duration of illness
course and radiological improvement were also taken
into consideration. So we took the change in chest
radiographic scores and the duration till improvement
as outcome measurements.
The outbreak of SARS posed great challenges. The
medical profession had less experience of this unprece-
dented and deadly disease. Although NHM is only a
supplementary treatment, these initial findings seem to
indicate a possible favorable effect of NHM on SARS or
SARS-like diseases in shortening the course of recovery.
All subjects treated with NHM A and B survived.
One patient from the placebo group expired. Although
our cases were too few to be conclusive, the initial
observations seem to indicate the possible benefit of
NHM on SARS or SARS-like diseases. The findings need
to be verified with a larger sample.
Discussion on mechanisms behind NHM treatment is
inevitably speculative. However, there are gaps in our
understanding of the immunopathogenesis of SARS (27).
This study was designed only to detect changes in IRS
and DI. Nevertheless, our literature review offers
significant insight worthy of further exploration on
SARS. Avendano and Booth reported that many SARS
cases in Toronto presented with hypocalcemia within
3 days of admission (6,14). We checked serum calcium in
one of our cases, which showed hypocalcemia on the
fourth day after the onset of disease (the second day of
admission). The major ingredient of our NHM A is a
mineral, Gypsum fibrosum (16gm, 13.3% of recipe by
weight), which contains mainly calcium sulfate, popularly
used for antipyretic and clearing the accumulated heat in
the lung according to the traditional Chinese medical
theory. We speculate that one of the effective mechanisms
of NHM A is associated with correction of electrolyte
imbalance that may play a very important role in
enhancing immunity. Some natural products have been
found to inhibit SARS-CoV 3C-like protease activity
(28). The mechanism of anti-SARS effect in natural
products merits further investigation.
Despite the encouraging results, our study still had
limitations. First, the sample size was small since we had
only eight cases of each group. However, within such a
short span of time and in view of the unpredictability of
the disease, enrollment was completely beyond our
control. Second, the study subjects were 54% positive
rate of SARS-CoV PCR or antibody. The SARS-CoV
PCR and antibody were not the necessary WHO criteria
of SARS during our study period. However, after
randomization procedure, the rate of positive SARS-
CoV PCR and antibody were balance among three
360 Additive effect of natural herbal medicine on SARSgroups. The results were also focused on SARS or SARS-
like diseases.
Like SARS, the threat of a possible pandemic due to
person-to-person transmission of avian influenza A
(H5N1) has aroused much concern among health
professionals (29). While different pathogens are involved
in SARS, SARS-like diseases and avian influenza, all of
them are severe infectious diseases with similar clinical
presentations (29,30) and pose serious adverse impact on
the respiratory system. We have learned from the
experience of using NHM as supplementary treatment
that it has potential benefits on SARS or SARS-like
infectious diseases or other contagious respiratory dis-
eases such as avian flu. Thus, it is desirable to conduct
similar studies and clinical trials in case of an outbreak of
avian influenza in the future.
Conclusion
The cases were too few to be conclusive, the initial
observations seem to indicate (i) NHM appears to be
safe in non-criticallly ill patients, (ii) clinical trials are
feasible in the setting of pandemic outbreaks and (iii) the
results of this study are encouraging but a large trial is
required to asses the efficacy of treatment.
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